Methods | We examined PSA screening data from the 2000, 2005, 2010, and 2013 National Health Interview Survey (NHIS) to determine the prevalence and determinants of screening before and after the 2012 USPSTF recommendations (draft released October 2011), as well as the association between the new USPSTF recommendations and the prevalence of screening. The NHIS is an in-person household survey, with multistage area probability sampling providing a representative sample of the US population; survey response rates were approximately 80%. This study received a waiver of institutional review board approval by the Brigham and Women's Hospital institutional review board.
Males aged 50 years or older who reported PSA testing within the 12 months preceding each year's survey were considered to have undergone screening. Exclusions included a history of prostate cancer and the answer "because of a problem" or "other reason," in response to the question, "What was the main reason you had this PSA test-was it part of a routine exam, because of a problem, or some other reason?"
We examined the prevalence of screening in all survey years and tested the association between survey year and the odds of screening before vs after the 2012 USPSTF recommendations with complex-sample logistic regression models (adjusted for race/ethnicity, region, marital status, educational attainment, insurance status, smoking status, household income, health care use, and personal health status). Pooled analyses of 2010 and 2013 survey data were first performed in the populations aged 75 years or older and in those younger than 75 years and a difference-in-differences analytic approach 4 was then used to evaluate whether the 2012 USPSTF recommendations were associated with a decrease in PSA screening in men younger than 75 years. Those aged 75 years or older were subject to previous recommendations against PSA screening and served as a control population. Results were weighted to reflect the US population based on the complex survey design. Statistical analyses were performed with SPSS version 21 (SPSS Inc). A 2-sided P value <.05 was the threshold for statistical significance. (Table) .
Results |
However After adjusting for patient factors, there were significant reductions in PSA screening associated with the 2012 USPSTF recommendations (difference-in-differences P < .001; Figure) .
Discussion | The 2008 USPSTF recommendations against PSA screening in men aged 75 years or older have not been associated with changes in screening practices.
2,5 However, we found a decrease in the prevalence of PSA screening following the 2012 recommendations, particularly in men younger than 75 years. These findings using nationally representative data suggest that younger men may be altering health care behavior at a higher rate than older men following the new USPSTF recommendations, changes in clinician PSA screening practices have occurred in response to the policy change, or both. Alternatively, the findings may reflect the broad effects of the economic recession on health care use or a delayed response to the 2008 guidelines.
Limitations of this study include relying on a single year of data after the USPSTF recommendations; nonresponse, recall and social desirability biases; limited regression model goodness of fit; and the inherent limitations of the differencein-differences study design. 
A Randomized Trial of Cardiovascular Responses to Energy Drink Consumption in Healthy Adults
Energy drink consumption has been associated with serious cardiovascular events, [1] [2] [3] [4] possibly related to caffeine and other stimulants. We hypothesized that drinking a commercially available energy drink compared with a placebo drink increases blood pressure and heart rate in healthy adults at rest and in response to mental and physical stress (primary outcomes). Furthermore, we hypothesized that these hemodynamic changes are associated with sympathetic activation, which could predispose to increased cardiovascular risk (secondary outcomes).
Methods | We conducted a randomized, double-blind, placebo-controlled, crossover pilot study. The trial protocol is available in the Supplement. Twenty-five healthy volunteers aged 18 years or older, who were nonsmokers, free of known disease, and not taking medications, were recruited by word-of-mouth from the local community. Each participant consumed a can (480 mL; 16 fl oz) of a commercially available energy drink (Rockstar; Rockstar Inc) and placebo drink within 5 minutes, in random order on 2 separate days, maximum 2 weeks apart. The placebo drink, selected to match the nutritional constituents of the energy drink, was similar in taste, texture, and color but lacked caffeine and other stimulants of the energy drink (240 mg of caffeine, 2000 mg of taurine, and extracts of guarana seed, ginseng root, and milk thistle).
The study was approved by the Mayo Clinic institutional review board. Informed written consent was obtained from participants. Data were collected at the Mayo Clinical Research Unit between August and November 2013.
Participants were fasting and abstained from caffeine and alcohol 24 hours prior to each study day. Serum levels of caffeine, plasma glucose, and norepinephrine were measured and blood pressure and heart rate were obtained at baseline and 30 minutes after drink ingestion. Hemodynamic measurements were also obtained during 2-minute physical, mental, and cold stressors performed in that order with 10-minute recovery times. Physical stress was performed by asking participants to sustain an isometric handgrip of onethird of maximum voluntary handgrip contraction, using a dynamometer. During mental stress, participants completed serial mathematical tasks as fast as possible. During the coldpressor test, performed last because of its sustained effects, participants immersed 1 hand into ice water.
Randomization was computer-generated using a randomized block design, with a block size of 6. Results are Error bars indicate 95% confidence intervals.
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